These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 29852782)

  • 61. The innovative potential of Lactobacillus rhamnosus LR06, Lactobacillus pentosus LPS01, Lactobacillus plantarum LP01, and Lactobacillus delbrueckii Subsp. delbrueckii LDD01 to restore the "gastric barrier effect" in patients chronically treated with PPI: a pilot study.
    Del Piano M; Anderloni A; Balzarini M; Ballarè M; Carmagnola S; Montino F; Orsello M; Pagliarulo M; Tari R; Soattini L; Sforza F; Mogna L; Mogna G
    J Clin Gastroenterol; 2012 Oct; 46 Suppl():S18-26. PubMed ID: 22955351
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Can We StoP Worrying about Long-term PPIs and Gastric Cancer Risk?
    Richman CM; Leiman DA
    Cancer Epidemiol Biomarkers Prev; 2023 Sep; 32(9):1127-1129. PubMed ID: 37655427
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology.
    Lundell L; Vieth M; Gibson F; Nagy P; Kahrilas PJ
    Aliment Pharmacol Ther; 2015 Sep; 42(6):649-63. PubMed ID: 26177572
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical use of proton-pump inhibitors but not H2-blockers or antacid/alginates raises the serum levels of amidated gastrin-17, pepsinogen I and pepsinogen II in a random adult population.
    Agréus L; Storskrubb T; Aro P; Ronkainen J; Talley NJ; Sipponen P
    Scand J Gastroenterol; 2009; 44(5):564-70. PubMed ID: 19263272
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors.
    Yu LY; Sun LN; Zhang XH; Li YQ; Yu L; Yuan ZQ; Meng L; Zhang HW; Wang YQ
    Adv Ther; 2017 May; 34(5):1070-1086. PubMed ID: 28429247
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effect of proton-pump inhibitor therapy on serum chromogranin a level.
    Pregun I; Herszényi L; Juhász M; Miheller P; Hritz I; Patócs A; Rácz K; Tulassay Z
    Digestion; 2011; 84(1):22-8. PubMed ID: 21304238
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Little necessity of acid inhibition against proton pump inhibitor rebound effects and prior helicobacter pylori eradication therapy in gastric ulcer patients: a randomized prospective study.
    Wada Y; Ito M; Takata S; Kitamura S; Takamura A; Tatsugami M; Imagawa S; Matsumoto Y; Tanaka S; Yoshihara M; Chayama K
    Hepatogastroenterology; 2009; 56(91-92):624-8. PubMed ID: 19621668
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Proton Pump Inhibitors: What the Internist Needs to Know.
    Spechler SJ
    Med Clin North Am; 2019 Jan; 103(1):1-14. PubMed ID: 30466666
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Friend or Foe.
    Gyawali CP
    Curr Gastroenterol Rep; 2017 Sep; 19(9):46. PubMed ID: 28780717
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Community-dwelling older adults' awareness of the inappropriate use of proton pump inhibitors.
    Rababa M; Rababa'h A
    BMC Geriatr; 2020 Oct; 20(1):431. PubMed ID: 33121444
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Pneumonia prevention in intubated patients given sucralfate versus proton-pump inhibitors and/or histamine II receptor blockers.
    Grindlinger GA; Cairo SB; Duperre CB
    J Surg Res; 2016 Dec; 206(2):398-404. PubMed ID: 27884335
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
    Hatlebakk JG; Berstad A
    Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
    [TBL] [Abstract][Full Text] [Related]  

  • 73. No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002-2014).
    Landi SN; Sandler RS; Pate V; Lund JL
    Gastroenterology; 2018 Mar; 154(4):861-873.e6. PubMed ID: 29122546
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Association between use of acid-suppressive drugs and risk of gastric cancer. A nested case-control study.
    Tamim H; Duranceau A; Chen LQ; Lelorier J
    Drug Saf; 2008; 31(8):675-84. PubMed ID: 18636786
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Alternative therapeutic approaches to chronic proton pump inhibitor treatment.
    Fass R
    Clin Gastroenterol Hepatol; 2012 Apr; 10(4):338-45; quiz e39-40. PubMed ID: 22178462
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Laparoscopic antireflux surgery for reflux esophagitis].
    Yano F; Omura N; Yanaga K
    Nihon Rinsho; 2016 Aug; 74(8):1316-1321. PubMed ID: 30562435
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Gastroesophageal reflux disease (GERD): is there more to the story?
    Vesper BJ; Altman KW; Elseth KM; Haines GK; Pavlova SI; Tao L; Tarjan G; Radosevich JA
    ChemMedChem; 2008 Apr; 3(4):552-9. PubMed ID: 18076011
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Therapy for peptic ulcer disease].
    Lukáš M
    Vnitr Lek; 2018; 64(6):595-599. PubMed ID: 30223656
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician.
    Huang JQ; Hunt RH
    Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):355-70. PubMed ID: 11403532
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies.
    Eom CS; Park SM; Myung SK; Yun JM; Ahn JS
    Ann Fam Med; 2011; 9(3):257-67. PubMed ID: 21555754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.